Website
News25/Ratings12
News · 26 weeks52+100%
2025-10-262026-04-19
Mix1490d
- Other7(50%)
- SEC Filings3(21%)
- Analyst2(14%)
- Earnings1(7%)
- Dividends1(7%)
Latest news
25 items- PRSystane Steps Up to the Plate as the Official Eye Drop of the Toronto Blue Jays, Raising Awareness of Dry Eye in CanadaNew partnership raises awareness of dry eye, a condition affecting an estimated 8.5 million Canadians1, helping fans stay comfortable throughout the game. This season, Alcon, the global leader in eye care dedicated to helping people see brilliantly, announced that Systane® has partnered with the Toronto Blue Jays as the official eye drop of the team. The partnership aims to help Canadians recognize the signs of dry eye and stay comfortable throughout the game. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260407095429/en/Systane Steps Up to the Plate as the Official Eye Drop of the Toronto Blue Jays, Raising Awareness of Dr
- PRAlcon Launches Clareon TruPlus, Enhanced Design Monofocal and Toric IOLs, at ASCRS 2026TruPlus is designed to increase depth of focus while maintaining the high-quality distance vision surgeons expect from a monofocal IOL1,2 TruPlus demonstrates higher distance image quality across pupil sizes and lighting conditions than TECNIS Eyhance3,* At ASCRS, Alcon will also feature more than 60 scientific presentations and peer-to-peer educational symposia Alcon (SIX/NYSE:ALC), the global leader in eye care dedicated to helping people see brilliantly, today announced the U.S. launch of Clareon® TruPlus, its new enhanced design monofocal and toric intraocular lens (IOL), at the American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting in Washington, D.C. TruP
- SECSEC Form 6-K filed by Alcon Inc.6-K - ALCON INC (0001167379) (Filer)
- PRAlcon Publishes Agenda for 2026 Annual General MeetingAlcon welcomes its shareholders to its fourth in-person AGM Alcon Board of Directors proposes to elect R. Scott Herren as a new independent Board member Proposed dividend of CHF 0.28 cash per share Alcon (SIX/NYSE:ALC), the global leader in eye care, will hold its Annual General Meeting (AGM) on April 30, 2026. Alcon is pleased to welcome shareholders to its fourth in-person AGM since becoming an independent, standalone company. The company looks forward to hearing directly from its shareholders at this open format meeting. Alcon's Board of Directors proposes to the AGM to elect R. Scott Herren as a new independent Board member. An accomplished financial executive with thirty-
- PRAlcon and LENSAR, Inc. Agree to Terminate Merger AgreementAlcon (SIX/NYSE:ALC), the global leader in eye care dedicated to helping people see brilliantly, today announced that it has entered into an agreement with LENSAR, Inc. (NASDAQ:LNSR) to terminate the companies' previously announced merger agreement. "Alcon continues to believe that the acquisition of LENSAR would have significantly enhanced FLACS innovation and competition to the benefit of surgeons and patients. However, the delay and associated costs of this extended regulatory review, which began nearly a year ago, has rendered the transaction unattractive to pursue further in light of the Federal Trade Commission's opposition. Alcon remains committed to advancing cataract surgery by d
- PRAlcon Surpasses 175 Million IOLs Implanted GloballyMilestone includes more than 6 million PCIOL implants worldwide, with PanOptix and Vivity leading globally in trifocal and EDOF IOLs1,* PanOptix delivers outstanding patient satisfaction and freedom from glasses; Vivity has a proven exceptionally low rate of visual disturbances2-8,**,Δ,§,^,‡ Alcon is committed to furthering innovation in the IOL space and plans to launch new technologies in key markets this year Alcon, the global leader in eye care dedicated to helping people see brilliantly, today proudly announced that more than 175 million of its intraocular lenses (IOLs) have been implanted worldwide.9,+ Alcon has more than 30 years of IOL experience with its robust portfolio
- ANALYSTAlcon upgraded by Wells Fargo with a new price targetWells Fargo upgraded Alcon from Equal Weight to Overweight and set a new price target of $97.00
- SECSEC Form 6-K filed by Alcon Inc.6-K - ALCON INC (0001167379) (Filer)
- SECSEC Form 20-F filed by Alcon Inc.20-F - ALCON INC (0001167379) (Filer)
- SECSEC Form 6-K filed by Alcon Inc.6-K - ALCON INC (0001167379) (Filer)
- PRAlcon Delivers Strong Fourth-Quarter 2025 Topline Growth as New Product Launches Accelerate SalesFourth-quarter 2025 sales of $2.7 billion, up 9% on a reported basis, or up 7% constant currency1 (cc), versus fourth-quarter 2024 Fourth-quarter 2025 diluted EPS of $0.44; core diluted EPS2 of $0.78 Generated $2.3 billion of cash from operations and $1.7 billion of free cash flow3 in full-year 2025 Returned $848 million to shareholders through share repurchases and dividends Ad Hoc Announcement Pursuant to Art. 53 LR Alcon (SIX/NYSE:ALC), the global leader in eye care, reported its financial results for the three and twelve month periods ending December 31, 2025. For the fourth quarter of 2025, sales were $2.7 billion, up 9% on a reported basis and up 7% on a constant curren
- PRAlcon Launches TOTAL30 Multifocal for Astigmatism, the World's Only Monthly Multifocal Toric Contact Lens with Water Gradient TechnologyProvides excellent end of day comfort even on day 30,^ helping patients stay in contact lenses† comfortably1 Designed for aging eyes, the Water Gradient Material offers 3x greater surface lubricity* and at least 5x softer lens surface2-3** Commercially available for Eye Care Professionals in the U.S. to meet the evolving visual needs of astigmatic presbyopes Alcon (SIX/NYSE:ALC), the global leader in eye care dedicated to helping people see brilliantly, today announced the U.S. launch of TOTAL30® Multifocal for Astigmatism, the world's only multifocal toric contact lens with Water Gradient Technology, helping patients stay in lenses comfortably,† as their vision changes from stand
- PRAlcon Debuts Groundbreaking PRECISION7 in Canada, a One-Week Replacement Contact Lens to Start and End Every Week FreshPRECISION7, a new one-week replacement lens, provides 16 hours of outstanding comfort and precise vision even on day 71 Features world's first ACTIV-FLO System specially designed for one-week optimal performance2 Now available in Canada, PRECISION7 broadens existing WaterInnovations portfolio, addressing the need for 16 hours of outstanding comfort and affordability when a daily disposable lens is not an option1,3 Alcon (SIX/NYSE:ALC), the global leader in eye care dedicated to helping people see brilliantly, today announced the Canadian launch of PRECISION7® sphere and toric, the only one-week replacement contact lens with the revolutionary ACTIV-FLO® System2,5 that provides 16 h
- ANALYSTWilliam Blair initiated coverage on AlconWilliam Blair initiated coverage of Alcon with a rating of Mkt Perform
- PRAlcon Completes $750 Million Share Repurchase ProgramAlcon Inc., the global leader in eye care dedicated to helping people see brilliantly, today announced the completion of its $750 million share repurchase program, which commenced on April 1, 2025. In aggregate, 9,301,877 registered shares were acquired on the SIX Swiss Exchange, representing 1.9% of the current share capital of Alcon Inc. The total buyback volume amounted to CHF 602 million (USD 750 million). The registered shares acquired will be held in treasury and are intended to offset the dilutive effect of registered shares vesting under Alcon's equity-based incentive plans. About Alcon Alcon helps people see brilliantly. As the global leader in eye care with a heritage span
- ANALYSTAlcon upgraded by Deutsche BankDeutsche Bank upgraded Alcon from Hold to Buy
- ANALYSTAlcon downgraded by StifelStifel downgraded Alcon from Buy to Hold
- SECSEC Form 6-K filed by Alcon Inc.6-K - ALCON INC (0001167379) (Filer)
- PRAlcon Terminates Agreement to Acquire STAAR SurgicalAd hoc announcement pursuant to Art. 53 LR Alcon (SIX/NYSE:ALC), the global leader in eye care dedicated to helping people see brilliantly, today terminated its definitive merger agreement with STAAR Surgical Company (NASDAQ:STAA) announced on August 5, 2025. "Throughout this process we remained disciplined with our views on price and risk. Moving forward, our refractive strategy is unchanged and our new wavelight® plus offering remains our focus for the most popular refractive surgery in the world, LASIK. This will be an exciting year for Alcon as we continue the global launches of more than 10 major products in both our surgical and vision care franchises. These innovations substantiv
- PRBroadwood Partners Comments on STAAR Surgical Shareholders' Rejection of the Company's Proposed Sale to AlconThanks Fellow Shareholders for Rejecting the Transaction Reiterates Enthusiasm for the Company's Standalone Prospects Looks Forward to Engaging with Board and Fellow Shareholders and Working Towards a Bright Future for STAAR Broadwood Partners, L.P. and its affiliates ("Broadwood" or "we"), which together own 30.2% of the outstanding common stock of STAAR Surgical Company ("STAAR" or the "Company") (NASDAQ:STAA), commented on the results of the Special Meeting of Shareholders (the "Special Meeting") that was held earlier today in connection with the proposed acquisition of STAAR by Alcon Inc. ("Alcon") (NYSE:ALC). Based on preliminary results, shareholders voted decisively to reject t
- PRAlcon to Present at 2026 Annual J.P. Morgan Healthcare ConferenceAlcon (SIX/NYSE:ALC) CEO David Endicott will present at the 2026 J.P. Morgan Healthcare Conference on Tuesday, January 13, 2026, at 8:15 a.m. PST. A live webcast of the conference will be available at investor.alcon.com/news-and-events/events-and-presentations. About Alcon Alcon helps people see brilliantly. As the global leader in eye care with a heritage spanning over 75 years, we offer the broadest portfolio of products to enhance sight and improve people's lives. Our Surgical and Vision Care products touch the lives of more than 260 million people in over 140 countries each year living with conditions like cataracts, glaucoma, retinal diseases and refractive errors. Our more than
- PRBroadwood Partners Denounces STAAR Surgical's Fourth Delay of the Shareholder Vote on the Company's Proposed Sale to AlconUrges Board to Allow Shareholders to Have Their Final Say on This Ill-Conceived Transaction Broadwood Partners, L.P. and its affiliates ("Broadwood" or "we"), which together own 30.2% of the outstanding common stock of STAAR Surgical Company ("STAAR" or the "Company") (NASDAQ:STAA), today responded to the fourth postponement of STAAR's Special Meeting of Shareholders (the "Special Meeting") in connection with the proposed acquisition of STAAR by Alcon Inc. ("Alcon") (NYSE:ALC). The Special Meeting, which was originally scheduled to be held on October 23, 2025, was adjourned in the face of then-pending rejection, rescheduled (following two subsequent postponements) to be held on December 1
- PRAlcon Exercises Right to Require STAAR Surgical to Adjourn its Special Meeting of StockholdersSTAAR Special Meeting of Stockholders Adjourned to January 6, 2026 STAAR Surgical Company (NASDAQ:STAA), the manufacturer of the Implantable Collamer® Lens (ICL) today announced that Alcon (SIX/NYSE:ALC) has exercised its right under the Alcon merger agreement to require STAAR to adjourn its Special Meeting of Stockholders in connection with the Alcon merger agreement (the "Special Meeting"). As a result, the Special Meeting, which was scheduled for December 19, 2025 at 8:30 a.m. Pacific Time, has been adjourned to January 6, 2026 at 8:30 a.m. Eastern Time. The record date for STAAR stockholders eligible to vote at the Special Meeting remains the close of business on October 24, 2025. Sto
- PRDefender Capital Reiterates Intention to Vote AGAINST STAAR Surgical's Proposed Sale to Alcon Inc.Expresses Disappointment in the Board's and Management's Continued Pursuit of Ill-advised Deal CHARLOTTE, N.C., Dec. 17, 2025 /PRNewswire/ -- Defender Capital ("Defender" or "we"), a long-term shareholder of STAAR Surgical Company ("STAAR" or the "Company") (NASDAQ: STAA) owning approximately 1.5% of the Company's outstanding common stock, today issued the following statement reiterating its intention to vote AGAINST the Company's proposed sale to Alcon Inc. ("Alcon") (NYSE:ALC) and expressing its disappointment in the Company's Board of Directors' (the "Board") continued pursuit of the deal: As shareholders of STAAR Surgical for the past decade, we remain convicted in the long-term potenti
- PRBroadwood Partners Issues Open Letter to STAAR Surgical Board Pledging Cooperation and Support When Vote on Alcon Transaction FailsExpresses Confidence in STAAR's Future and the Opportunity for Significant Value Creation Believes STAAR is Worth at Least $50 Per Share If the Company Is Run in Best Interest of Shareholders Broadwood Partners, L.P. and its affiliates (collectively, "Broadwood") today issued the following letter to the Board of Directors (the "Board") of STAAR Surgical Company ("STAAR" or the "Company") (NASDAQ:STAA). Broadwood, which owns 30.2% of STAAR's outstanding common stock, continues to urge its fellow shareholders to vote "AGAINST" the proposed acquisition of STAAR by Alcon Inc. ("Alcon") (NYSE:ALC). Shareholders can find additional information at www.LetSTAARShine.com. December 17, 2025 STAA